BioAtla, Inc.
BCABNASDAQHealthcare● Active
$3.31
$-0.02(-0.60%)
Market Cap$4174023
P/E Ratio—
52W High$71.5
52W Low$3.12
BioAtla, Inc. (BCAB) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BCAB · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.00M | $11.00M | $0.00M | $0.00M | $0.25M |
| Cost of Revenue | $0.00M | $0.93M | $1.22M | $1.20M | $0.00M |
| Gross Profit | $2.00M | $10.07M | ($1.22M) | ($1.20M) | $0.25M |
| Gross Margin %(computed) | 100.00% | 91.59% | — | — | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $43.57M | $63.09M | $103.73M | $79.35M | $58.27M |
| G&A Expenses | $17.73M | $21.85M | $25.96M | $28.79M | $38.42M |
| Total Operating Expenses | $61.30M | $84.02M | $128.47M | $106.94M | $96.69M |
| Operating Income | ($59.30M) | ($73.94M) | ($129.69M) | ($108.14M) | ($96.44M) |
| Operating Margin %(computed) | — | -672.21% | — | — | — |
| Interest Income | $0.84M | $3.37M | $6.31M | $1.65M | $0.35M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($59.61M) | ($69.78M) | ($123.46M) | ($106.48M) | ($95.40M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($59.61M) | ($69.78M) | ($123.46M) | ($105.28M) | ($95.40M) |
| Net Margin %(computed) | — | -634.33% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-50.50 | $-72.00 | $-129.00 | $-137.00 | $-138.00 |
| Wtd Avg Shares | 1.18M | 0.97M | 0.96M | 0.78M | 0.69M |
| EBITDA | ($58.93M) | ($73.02M) | ($122.24M) | ($105.28M) | ($94.07M) |
| EBITDA Margin %(computed) | — | -663.80% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more BioAtla, Inc. data
About BioAtla, Inc. (BCAB) Income Statement
BioAtla, Inc. (BCAB) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BCAB reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.06B) — a net profit margin of -2980.35%.
Frequently asked questions
BCAB · 4 questionsBioAtla, Inc. (BCAB) reported revenue of $0.00B for 2025, down 81.8% year-over-year.
BCAB revenueBCAB salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09